ClinicalTrials.gg
CompletedNCT01088191Updated Aug 15, 2018

Safety and Efficacy Study of MSB-CAR001 in Subjects 6 Weeks Post an Anterior Cruciate Ligament Reconstruction

A Phase 1/2 interventional study of MSB-CAR001 Combined With Hyaluronan and Hyaluronan in Anterior Cruciate Ligament Injury and Osteoarthritis, sponsored by Mesoblast, Ltd.. Completed at 1 site in Australia. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2018-08-15.

Sponsored by Mesoblast, Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate safety and preliminary efficacy of MSB-CAR001 in subjects who have recently undergone an Anterior Cruciate Ligament Reconstruction

Read the detailed description

This is a prospective, single center, randomized, double blind, controlled Phase 1b/2a study designed to evaluate the safety and tolerability of a single injection into the knee joint of two different doses of MPCs combined with Hyaluronan compared to Hyaluronan alone in patients who have recently undergone an Anterior Cruciate Ligament Reconstruction.

All subjects in this study have undergone unilateral ACL reconstruction surgery within six months of injury. MSB-CAR001 plus Hyaluronan at one of two doses or Hyaluronan alone will be injected into the knee joint.

After the screening and injection visits, each subject will be evaluated clinically within 3 days and 28 days after surgery, and at 2, 3, 6, 9, 12, 18, and 24 months after surgery. The radiographical exams will be performed at 6, 12, 18, and 24 months after surgery.

Subjects will be evaluated at 24 months after surgery for safety.

02

Conditions studied

  • Anterior Cruciate Ligament Injury
  • Osteoarthritis

Keywords

  • Acute Anterior Cruciate Ligament Injury
  • Anterior Cruciate Ligament Reconstruction
  • Adult Stem Cells
  • Mesenchymal precursor cells
03

In context

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

This study's enrollment of 17 is below the median of 56 across 460 interventional studies indexed under Anterior Cruciate Ligament Injuries.

Browse Anterior Cruciate Ligament Injuries studies →

Lead sponsor

Mesoblast, Ltd. is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females at least 18 years of age, but not older than 40
  2. ACL injury requiring reconstruction
  3. Have undergone unilateral ACL reconstruction surgery within six months of injury;
  4. Willing and able to undertake a standardized rehabilitation protocol
  5. ACL graft used is autograft
  6. Willingness to participate in follow-up for 24 months from the time of initial treatment
  7. Ability to understand and willingness to sign consent form

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or breast feeding or planning to become pregnant during the study
  2. Previous allergic reaction to Hyaluronan
  3. Systemic or local infection at the screen visit or at the time of the study injection
  4. History of any disease, such as, systemic lupus erythematosus, Addison's disease, Crohn's disease, or rheumatoid arthritis
  5. Treatment with therapy within 6 months prior to screen (visit 1)
  6. Acute or chronic infectious disease, including but not limited to (HIV);
  7. Treatment and /or uncompleted follow-up treatment of any therapy within 6 months before the procedure and /or intent to participate in any other investigational drug or cell therapy study during the 24 month follow-up period of this study;
  8. Recipient of prior allogeneic stem cell/progenitor cell therapy
  9. Undergoing a simultaneous procedure to the opposite knee
  10. 20% or greater anti-human leukocyte antigen (HLA) antibody titer and/or has antibody specificities to donor HLA antigens;
  11. Known sensitivities to bovine (cow), murine (mouse), chicken products and/or dimethylsulfoxide (DMSO). Previous allergic reaction to Hyaluronan;
  12. History or current evidence of alcohol or drug abuse or is a recreational user of illicit drugs or prescription medications
  13. History of prior surgery to the study knee joint
  14. History of (excluding basal cell carcinoma that has been successfully excised)
  15. Chondral lesions noted at time of surgical reconstruction greater than Grade 1a on any surfaces
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
17 participants (actual)

Study arms

  • Active comparator
    Hyaluronan Alone

    Hyaluronan Alone

    Biological: MSB-CAR001 Combined With Hyaluronan · Drug: Hyaluronan

  • Experimental
    MSB-CAR001

    Single Dose of MSB-CAR001 Combined With Hyaluronan

    Biological: MSB-CAR001 Combined With Hyaluronan

Interventions

  • BiologicalMSB-CAR001 Combined With Hyaluronan

    Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan

    Also known as: Anterior Cruciate Ligament Reconstruction, Adult Stem Cells, Knee Injection

  • DrugHyaluronic AcidStudies of Hyaluronic AcidHyaluronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Hyaluronan alone

    Also known as: Active Control

06

What researchers measure

Primary outcomes

  1. To determine the overall safety of MSB-CAR001 plus carrier using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and immunology).

    Time frame: 2 years

Secondary outcomes

  1. To evaluate the overall efficacy with MSB-CAR001 plus Hyaluronan compared to Hyaluronan alone using MRI scans and x-ray of the involved knee joint and access the change in outcomes (KOOS, SF-36) and pain (VAS)

    Time frame: 2 years

07

Study locations

1 site
  • Emeritus Research
    Malvern East, Victoria 3145, Australia
08

References and documents

Publications

  • Wang Y, Shimmin A, Ghosh P, Marks P, Linklater J, Connell D, Hall S, Skerrett D, Itescu S, Cicuttini FM. Safety, tolerability, clinical, and joint structural outcomes of a single intra-articular injection of allogeneic mesenchymal precursor cells in patients following anterior cruciate ligament reconstruction: a controlled double-blind randomised trial. Arthritis Res Ther. 2017 Aug 2;19(1):180. doi: 10.1186/s13075-017-1391-0. PubMed 28768528 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Nov 2013 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2010
First posted
Mar 17, 2010
Start
Mar 2009
Primary completionActual
Nov 2013
CompletionActual
Oct 2014
Last update
Aug 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01088191
Lead sponsor
Mesoblast, Ltd.
Responsible party
Sponsor
First posted
Mar 17, 2010
Start date
Mar 2009
Primary completion
Nov 2013
Completion
Oct 2014
Last update
Aug 15, 2018

Study contacts

Donna Skerrett, MD
study director · Mesoblast, Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion